Cidara Therapeutics

Cidara Therapeutics, a San Diego biotech, is advancing rezafungin acetate—a long‑acting echinocandin antifungal—for invasive candidiasis, and its Cloudbreak platform for antiviral Fc‑conjugates targeting influenza, RSV and COVID‑19, with Phase 1/2a studies underway.

Headquarters: United States (USA)

Cidara Therapeutics Logo
Company Profile
  • Employees: 38
  • HQ: San Diego
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
CDTX Cidara Therapeutics
Cap: 7.0B
EQUITY NMS USD US1717571079 Active
📈
Home Login